Risk stratification of neutropenic sepsis: is NEWS comparable to MASCC
Research type
Research Study
Full title
Risk stratification of neutropenic sepsis: is NEW score comparable to MASCC score?\n\nNEWS (national early warning score)\nMASCC (mulit-national association for supportive care in cancer)
IRAS ID
215240
Contact name
Louise . J . McKee
Contact email
Sponsor organisation
Newcastle University
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
The purpose of this study is to determine whether the NEW (national early warning) score is comparable to the MASCC (multinational association for supportive care in cancer) score when used as a risk categorisation tool to estimate risk of complications from neutropenic sepsis. Neutropenic sepsis is an infection which occurs when someone’s blood has to few neutrophils (a type of white blood cells) to fight that infection. This can occur when a patient has received systemic anti-cancer treatment. The current Scottish neutropenic sepsis guidelines use the NEW score as a risk categorisation tool. The risk category determines the intensity of intravenous antibiotic therapy patients will receive. The NEW score was not designed to be a risk categorisation tool for neutropenic sepsis and is not validated. It was designed as a scored communication tool which uses physiological parameters to ensure a timely response to and assessment of any acutely unwell patient in hospital. The MASCC score was specifically designed as a tool to estimate risk of complications from neutropenic sepsis due to anti-cancer treatment and has been internationally and prospectively validated for that purpose. Using data that was collected routinely we will estimate risk of complications from neutropenic sepsis using the MASCC score and compare this with the risk estimated using the NEW score. All patients at Aberdeen Royal Infirmary who have developed neutropenic sepsis because of their anti-cancer treatment will be eligible for this study. Data will be collected retrospectively after the completion of a patient’s episode of care for neutropenic sepsis. Patients will not be asked to give any additional information. The study will be conducted over a 6 month period.\n\n\n\n\n\n
REC name
North of Scotland Research Ethics Committee 1
REC reference
17/NS/0014
Date of REC Opinion
27 Apr 2017
REC opinion
Further Information Favourable Opinion